Actively Recruiting
A Phase IIa Randomized Study of SHR-1905 Injection for Treating Moderate to Severe Atopic Dermatitis in Adults
Led by Guangdong Hengrui Pharmaceutical Co., Ltd · Updated on 2026-04-08
75
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of SHR-1905 injection in adults with moderate-to-severe atopic dermatitis, a condition causing significant skin inflammation. This randomized, double-blind, placebo-controlled Phase IIa study aims to better understand how well SHR-1905 works and how safe it is for this patient group. The trial is sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd and focuses on measuring improvements in skin condition and itch severity. Participants will be randomly assigned to receive either one of two doses of SHR-1905 injection or a placebo. The study treatment is given as an injection, and participants are monitored over 16 weeks for key skin health outcomes. The trial includes multiple assessment points from day 14 through day 252, tracking changes in skin severity scores and itch levels to observe the treatment effects over time. During the study, participants will have regular evaluations including measurements of the Eczema Area and Severity Index EASI, Investigators Global Assessment IGA, and Itch Numeric Rating Scale Itch-NRS. Adverse events are also monitored throughout the study period. The main outcome focuses on the proportion of participants achieving a 75% or greater reduction in their EASI score by week 16. Total participation duration may extend beyond 16 weeks to include follow-up assessments up to day 252.
CONDITIONS
Brief Title
A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis
Research Team
R
Ran Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here